



# The 8th International Conference of the International Mesothelioma Interest Group

**Conference Chairs:  
Hedy Lee Kindler, MD and Samuel Armato, PhD**

**October 19-22, 2006  
The Sheraton Chicago Hotel & Towers  
Chicago, Illinois**



**Hosted by:  
The University of Chicago  
Pritzker School of Medicine  
[imig.uchicago.edu](http://imig.uchicago.edu)**

## International Organizing Committee

Steven Albelda, Philadelphia, Pennsylvania  
H. Richard Alexander, Baltimore, Maryland  
Paul Baas, Amsterdam, The Netherlands  
Hasan Batirel, Istanbul, Turkey  
Courtney Broaddus, San Francisco, California  
Raphael Bueno, Boston, Massachusetts  
Sjaak Burgers, Amsterdam, The Netherlands  
Helen Clayson, Cumbria, United Kingdom  
Thomas Colby, Rochester, Minnesota  
Jenette Creaney, Perth, Australia  
Nicholas de Klerk, Subiaco, Australia  
Irma Dianzani, Novara, Italy  
James Entwisle, Leicester, United Kingdom  
Dean Fennell, Belfast, United Kingdom  
Francoise Galateau-Salle, Caen, France  
Gunnar Hillerdal, Stockholm, Sweden  
Raffit Hassan, Bethesda, Maryland  
Aliya Husain, Chicago, Illinois  
Pasi Janne, Boston, Massachusetts  
Tushar K. Joshi, Delhi, India  
Robert Kratzke, Minneapolis, Minnesota  
Richard Lake, Perth, Australia  
Christian Manegold, Mannheim, Germany  
Brooke Mossman, Burlington, Vermont  
Martin Muers, Leeds, United Kingdom  
Steven Mutsaers, Perth, Australia  
Luciano Mutti, Vercelli, Italy  
Anna Nowak, Perth, Australia  
Bruce Robinson, Perth, Australia  
Oluf Dimitri Roe, Trondheim, Norway  
Ravi Salgia, Chicago, Illinois  
Rolf Stahel, Zurich, Switzerland  
Jeremy Steele, London, United Kingdom  
Daniel Stermann, Philadelphia, Pennsylvania  
David Sugarbaker, Boston, Massachusetts  
Paul Sugarbaker, Washington, DC  
Joseph Testa, Philadelphia, Pennsylvania  
James teWaterNaude, Capetown, South Africa  
Walter Weder, Zurich, Switzerland  
Chi Pang Wen, Taipei, Taiwan

## PROGRAM OVERVIEW

### The 8th International Conference of the International Mesothelioma Interest Group

#### Wednesday, October 18, 2006

**7:30-9:30 pm Welcome Reception**  
**The Signature Room**  
**95th floor of the John Hancock Center**

#### Thursday, October 19, 2006

**7:00-8:00 Registration/Continental Breakfast**

**8:00-8:05 Introduction and Welcome**  
Hedy Lee Kindler and Samuel Armato  
IMIG Conference Co-Chairs

**8:05-9:55 The High-Risk Individual I**  
**Session Chair:** Joseph Testa (Philadelphia, PA) and Karl Kelsey (Boston, MA)

**8:05-8:25 The mesothelioma epidemic in Cappadocia: The gene-environment interaction**  
Michele Carbone, Honolulu, HI

**8:25-8:40 Abstract: Familial clustering of mesothelioma in subjects exposed to crocidolite at Wittenoom**  
Nicholas de Klerk, Subiaco, Australia

**8:40-9:00 Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study**  
Irma Dianzani, Novara, Italy

**9:00-9:20 A mouse model recapitulating genetic and signaling perturbations characteristic of human mesothelioma**  
Joseph Testa, Philadelphia, PA

**9:20-9:40 Chemoprevention as an approach to control of carcinoma of the lung and mesothelioma**  
Michael Sporn, Hanover, NH

**9:40-9:55 Abstract: Vitamin A and cancer prevention in workers previously exposed to asbestos in Wittenoom**  
Helman Alfonso, Crawley, Australia  
**IMIG Young Investigator Award**

**9:55-10:15 Break/Poster Viewing**

**10:15-11:40 The High-Risk Individual II**

**Session Chairs:** Oluf Dimitri Roe (Trondheim, Norway) and Kyle Hogarth (Chicago, IL)

**10:15-10:35 Biomarkers for malignant mesothelioma**

Jenette Creaney, Perth, Australia

**10:35-10:55 Genomics for biomarker detection in mesothelioma**

Harvey Pass, New York, NY

**10:55-11:10 Abstract: Diagnostic and prognostic utility of soluble mesothelin-related peptides in malignant pleural mesothelioma**

Bogdan-Dragos Grigoriu, Lille, France

**11:10-11:25 ALA mediated fluorescence thoracoscopy in pleural diseases**

Sjaak Burgers, Amsterdam, The Netherlands

**11:25-11:40 Low-dose computed tomography in prior asbestos workers**

Heidi Roberts, Toronto, Canada

**11:40-12:40 Lunch**

**12:40-2:00 Pathogenesis: How Does Asbestos Cause Cancer?**

**Session Chairs:** Marie-Claude Jaurand (Paris, France) and Michele Carbone (Honolulu, HI)

**12:40-1:00 Plasticity of the mesothelium: A stem cell in the midst?**

Steven Mutsaers, Perth, Australia

**1:00-1:20 Cell signaling and transcription factor activation by asbestos**

Brooke Mossman, Burlington, VT

**1:20-2:00 DEBATE**

**SV40 plays a causative role in mesothelial cell carcinogenesis**

Adi Gazdar, Dallas, TX

**SV40 as a significant carcinogen in human mesothelioma and other cancers: An increasingly dubious hypothesis**

Marc Ladanyi, New York, NY

**Moderator:** Steven Albelda, Philadelphia, PA

**2:00-2:30 Break/Poster Viewing**

**2:30-4:15 Workshop: The Clinical Relevance of Mouse Models for Mesothelioma**

**Co-Chairs:** Richard Lake (Perth, Australia) and Sjaak Burgers (Amsterdam, The Netherlands)

**2:30-2:40 Animal models: An overview**

Steven Albelda, Philadelphia, PA

**2:40-2:45 An SV40 TAg transgenic model of asbestos-induced mesothelioma**

Richard Lake, Perth, Australia

**2:45-2:55 Abstract: Gene expression profiling in an SV40 large T antigen expressing transgenic mouse mesothelioma model. Implications for a role for SV40 in human mesothelioma?**

Andrew Holloway, East Melbourne, Australia

**IMIG Young Investigator Award**

**2:55-3:00 A conditional knockout model for mesothelioma**

Sjaak Burgers, Amsterdam, The Netherlands

**3:00-3:10 Abstract: A conditional knockout model for malignant mesothelioma. A model for in vivo and in vitro therapeutic strategies**

Johan Jongasma, Amsterdam, The Netherlands

**3:10-3:20 Abstract: Loss of functional Arf predisposes mice to asbestos-induced mesothelioma**

Deborah Altomare, Philadelphia, PA

**3:20-3:30 Abstract: Local recurrence model of malignant pleural mesothelioma and investigation of local adjuvant treatment after surgery**

Walter Weder, Zurich, Switzerland

**3:30-3:40 Abstract: Development of a malignant mesothelioma model with defined genetic elements**

Tan Ince, Boston, MA

**3:40-3:50 Abstract: Tumor infiltrating macrophages in murine malignant mesothelioma: Targeting macrophages for tumor therapy**

Bernadette Scott, Victoria, Australia

**3:50-4:15 DISCUSSION**

**Posters**

**SV40 oncoproteins and p53 deficiency impair stress-induced mesothelial cell senescence**

Jodie Pietruska, Providence, RI

**Monitoring tumor growth by imaging of a human mesothelioma murine model**

Pietro Bertino, Novara, Italy

**A novel murine mesothelioma model of malignant pleural effusion**

Masaki Anraku, Toronto, Canada

**Clinico-pathologic features of murine mesothelioma induced by natural or synthetic fibers**

Pascal Andujar, Creteil, France

**2:30-4:15 Workshop: Developing the Next Generation of Clinical Trials for Mesothelioma: What are the Key Questions and How Should We Answer Them?**

**Co-Chairs:** Anna Nowak (Perth, Australia) and Paul Baas (Amsterdam, The Netherlands)

**2:30-2:45 Potential pitfalls in the evaluation of new drugs for mesothelioma: Lessons from the past**  
Paul Baas, Amsterdam, The Netherlands

**2:45-2:55 Abstract: Prognosis of malignant pleural mesothelioma: Subtype more important than stage. A study from the Nordic Mesothelioma Groups**  
Gunnar Hillerdal, Stockholm, Sweden

**2:55-3:10 Design issues in phase II/III clinical trials in mesothelioma**  
Richard Stephens, London, United Kingdom

**3:10-3:25 Functional and patient-rated endpoints in clinical trials**  
Anna Nowak, Perth, Australia

**3:25-3:40 Is there a correlation between pathologic response and radiographic response and what does this mean?**  
Dean Fennell, Belfast, United Kingdom

**3:40-4:15 PANEL DISCUSSION**  
Jeremy Steele, London, United Kingdom

**5:30-9:30 Field Museum Extravaganza**

**4:45 Trolleys depart from the Sheraton Chicago Hotel & Towers**

**5:30-7:30 Guided tour of the exhibition, "Tutankhamun and the Golden Age of Pharaohs"**

**7:30-9:30 Dinner**

**9:30 Trolleys return to the Sheraton Chicago Hotel & Towers**

**Friday, October 20, 2006**

**7:00-8:00 Continental Breakfast**

**8:00-10:05 Epidemiology I**

**Session Chairs:** Gunnar Hillerdal (Stockholm, Sweden) and Julian Peto (London, United Kingdom)

**8:00-8:20 South Africa: The first link between asbestos and mesothelioma, but not the last word?**  
James teWaterNaude, Capetown, South Africa

**8:20-8:40 The mesothelioma epidemic: Occupational, environmental, and spontaneous cases**  
Julian Peto, London, United Kingdom

**8:40-8:55 Abstract: The global asbestos epidemic and its reflections in the recent Japanese experience**  
Ro-Ting Lin, Kitakyushu, Japan  
**IMIG Young Investigator Award**

**8:55-9:10 Abstract: Risk of pleural mesothelioma: A French population-based case control study (1998-2002)**  
Patrick Rolland, Bordeaux, France

**9:10-9:30 Health effects among World Trade Center responders**  
Steven Levin, New York, NY

**9:30-9:50 Pleural abnormalities and exposure to asbestos-contaminated vermiculite in Libby, Montana: A twenty year follow-up study**  
James Lockey, Cincinnati, OH

**9:50-10:05 Abstract: Mesothelioma update for Libby, Montana: Occupational and non-occupational**  
Bruce Case, Montreal, Canada

**10:05-10:30 Break/Poster Viewing**

**10:30-12:20 Epidemiology II**

**Session Chairs:** Tushar K. Joshi (Delhi, India) and Chi Pang Wen (Taipei, Taiwan)

**10:30-10:50 Australia: Wittenoom and beyond**  
Nicholas de Klerk, Subiaco, Australia

**10:50-11:05 Abstract: Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite)**  
Alison Reid, Crawley, Australia

**11:05-11:25 The rising toll of mesothelioma in Egypt**  
Rabab Gaafar, Cairo, Egypt

- 11:25-11:40 Mesothelioma in Turkey: A rural disease**  
Muzaffer Metintas, Eskisehir, Turkey
- 11:40-12:00 Asbestos-related diseases from environmental exposure to crocidolite in Da-yao, China: An update study on mesothelioma and lung cancer mortality from a residentially exposed cohort and from local surveys and statistics**  
Chi Pang Wen, Taipei, Taiwan
- 12:00-12:20 Asbestos use in India: Magnitude of risk and impact on health**  
Tushar K. Joshi, Delhi, India
- 10:20-12:30 Workshop: Immunology and Immunotherapy of Mesothelioma**  
**Co-Chairs:** Bruce Robinson (Perth, Australia) and Steven Albelda (Philadelphia, PA)
- 10:20-10:35 Combining immunotherapy with chemotherapy to treat mice with mesothelioma**  
Richard Lake, Perth, Australia
- 10:35-10:50 What is the evidence in patients that there is any immune response to mesothelioma and/or that immunotherapy ever works?**  
Bruce Robinson, Perth, Australia
- 10:50-11:00 Abstract: Targeting the tumor microenvironment: A novel immunotherapy that cures large mesothelioma tumors by engaging neutrophils, CD8+ T cells, and tumor blood vessels**  
Delia Nelson, Bentley, Australia
- 11:00-11:15 Altering the tumor microenvironment to augment immunotherapy for mesothelioma**  
Steven Albelda, Philadelphia, PA
- 11:15-11:45 The importance of stroma in the development and destruction of cancers**  
Hans Schreiber, Chicago, IL
- 11:45-12:00 Antibody-based treatment for mesothelioma: Clinical trials and laboratory studies**  
Raffit Hassan, Bethesda, MD
- 12:00-12:10 Abstract: Murine mesothelioma treatment with peri-tumoral injections of CpG alone or combined with CD40 ligand**  
Richard Kornbluth, La Jolla, CA
- 12:10-12:20 Abstract: Dendritic cell-based immunotherapy for malignant pleural mesothelioma**  
Joost Hegmans, Rotterdam, The Netherlands
- 12:20-12:30 Abstract: Identifying and targeting a spectrum of internalizing cell surface antigens expressed by mesothelioma**  
Bin Liu, San Francisco, CA

## Posters

- Immune profile of peripheral and pleural fluid T cells in malignant mesothelioma and pleural metastasis of adenocarcinoma**  
Arnaud Scherpereel, Lille, France
- Stimulation of macrophage toxicity for mesothelioma cells by anti-CD14 antibody**  
Marie-Marthe Phillippeaux, Geneva, Switzerland
- A photodynamic therapy generated tumor vaccine in an orthotopic murine malignant mesothelioma model**  
Joseph Friedberg, Philadelphia, PA
- Chemokine receptors are rarely expressed on malignant or benign mesothelial cells**  
Ben Davidson, Oslo, Norway
- Efficient induction of mesothelioma-specific cytotoxic T cell responses by cross presentation of apoptotic HSP70-overexpressing mesothelioma cells by dendritic cells**  
Marc Gregoire, Nantes, France

## 12:20-1:45 Lunch

### 1:45-3:15 Genetics

**Session Chairs:** Andrew Holloway (East Melbourne, Australia) and Raphael Bueno (Boston, MA)

- 1:45-2:05 Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma**  
Marie-Claude Jaurand, Paris, France
- 2:05-2:20 Abstract: Asbestos-associated malignancies in the lung and pleura show distinct genetic aberrations**  
Pamela Lindholm, Helsinki, Finland
- 2:20-2:40 Proteomic methods to identify novel therapeutic targets in malignant mesothelioma**  
Pasi Janne, Boston, MA
- 2:40-2:55 Abstract: Gene expression profiling of malignant peritoneal mesothelioma identifies novel targets for therapeutic intervention**  
Sheelu Varghese, Baltimore, MD  
**IMIG Young Investigator Award**
- 2:55-3:15 Prognostic gene ratio test for mesothelioma validated in a prospective clinical trial**  
Raphael Bueno, Boston, MA

### 3:15-3:40 Break/Poster Viewing

### 1:45-5:45 Supportive Care Satellite Symposium

**Co-Chairs:** Martin Muers (Leeds, United Kingdom) and Helen Clayson (Cumbria, United Kingdom)

- 1:45-2:10 The scope of supportive palliative care for malignant mesothelioma in the 21st century**  
Martin Muers, Leeds, United Kingdom
- 2:10-2:35 The management of breathlessness in mesothelioma**  
Sara Booth, Cambridge, United Kingdom
- 2:35-3:00 Managing pain in mesothelioma**  
WWA Zurmond, Amsterdam, The Netherlands
- 3:00-3:10 *Abstract:* Malignant mesothelioma and cachexia: Description of body composition changes in 27 patients receiving chemotherapy**  
Nick Pavlakis, Sydney, Australia
- 3:10-3:35 Managing effusions: When and how to intervene**  
Daniel Miller, Atlanta, GA
- 3:35-3:45 *Abstract:* Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients**  
Guntulu Ak, Eskisehir, Turkey
- 3:45-3:55 *Abstract:* The evaluation of local dissemination on intervention sites in malignant pleural mesothelioma patients and indications for prophylactic radiotherapy**  
Huseyin Yildirim, Eskisehir, Turkey  
**IMIG Travel Award**
- 3:55-4:10 BREAK**
- 4:10-4:35 Patients' and carers' experience of mesothelioma**  
Helen Clayson, Cumbria, United Kingdom
- 4:35-4:55 The nurse's role in mesothelioma**  
Tamara Guterz, Chicago, IL
- 4:55-5:20 Asbestos disease: A Canadian case study**  
James Mackenzie, Sarnia, Canada
- 5:20-5:45 PANEL DISCUSSION**

#### Posters

##### Rates of thromboembolic events in patients with mesothelioma

Claire Verschraegen, Albuquerque, NM

##### Increased pleural fluid ADA level in patients with malignant mesothelioma: A potential predictor for the outcome of talc pleurodesis

Huseyin Yildirim, Eskisehir, Turkey

##### Developing a National Resource Centre for Mesothelioma in the UK

Liz Darlison, Leicester, United Kingdom

### 3:45-5:45 Imaging Workshop

**Co-Chairs:** Samuel Armato (Chicago, IL) and James Entwisle (Leicester, United Kingdom)

- 3:45-4:05 Imaging malignant pleural mesothelioma: Clinical applications and challenges**  
James Entwisle, Leicester, United Kingdom
- 4:05-4:25 The evolution of imaging-based tumor response evaluation in mesothelioma**  
Samuel Armato, Chicago, IL
- 4:25-4:40 *Abstract:* Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma**  
Anna Nowak, Perth, Australia
- 4:40-4:55 *Abstract:* Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18F-fluorodeoxyglucose**  
Giovanni Luca Ceresoli, Milan, Italy
- 4:55-5:10 *Abstract:* Development of a computer model for volumetric response assessment in mesothelioma**  
Binsheng Zhao, New York, NY
- 5:10-5:45 PANEL DISCUSSION**  
James Entwisle (Leicester, UK), Heber MacMahon (Chicago, IL), Mylene Truong (Houston, TX) and Samuel Armato (Chicago, IL)

#### Posters

##### FDG PET/CT in malignant pleural mesothelioma: Is there a histological difference between hot and cold areas?

Peter Kestenholz, Zurich, Switzerland

##### Molecular bioprobes for imaging malignant mesothelioma

Ripen Misri, Vancouver, Canada

##### Spontaneous regression of diffuse malignant pleural mesothelioma with no treatment: Two case reports

Astero Klabatsa, London, United Kingdom

### 3:40-5:55 Tumor Biology: Oral Abstracts and Poster Discussion

**Session Chairs:** Steven Mutsaers (Perth, Australia) and Pasi Janne (Boston, MA)

- 3:40-3:55 *Abstract:* Asbestos burden, epigenetic silencing, and survival in malignant pleural mesothelioma**  
Brock Christensen, Boston, MA  
**IMIG Young Investigator Award**
- 3:55-4:10 *Abstract:* Pathway signatures of biphasic and epithelial mesothelioma identify the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors**  
Charles Powell, New York, NY

- 4:10-4:25 Abstract: TNF- $\alpha$  inhibits asbestos-induced cytotoxicity via a NF- $\kappa$ B dependent pathway: A possible mechanism for asbestos-induced oncogenesis**  
Haining Yang, Honolulu, HI
- 4:25-4:40 Abstract: Oxidative stress gene modulation in pleural mesothelioma as assessed by microarray in vitro, ex-vivo, and in-situ analysis**  
Bertrand Rihn, Nancy, France
- 4:40-4:55 Abstract: NF- $\kappa$ B provides a survival signal to human mesothelial and mesothelioma cells exposed to asbestos fibers**  
Luciano Mutti, Vercelli, Italy
- 4:55-5:05 Abstract: Semi-quantitative analysis of growth factor gene expression in the lungs and pleura by laser capture microscopy**  
Arnold Brody, New Orleans, LA

## Poster Discussion

**Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in humans**  
Michele Carbone, Honolulu, HI

**Microarray of normal mesothelium and mesothelioma—visceral and parietal pleura has distinct gene expression profile—consequences for oncogenesis of mesothelioma?**  
Oluf Dimitri Roe, Trondheim, Norway

**Ras pathway activation in malignant mesothelioma**  
Robert Kratzke, Minneapolis, MN

**5:05-5:20 Discussant:** Steven Mutsaers, Perth, Australia

**Alterations of the G1 checkpoints in malignant pleural mesothelioma in relation to pathogenesis and survival**  
Rabab Gaafar, Cairo, Egypt

**An integrated analysis of chromosomal alteration and gene expression in malignant mesothelioma**  
Andrew Holloway, East Melbourne, Australia

**Expression of Snail, Slug, and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression**  
Ben Davidson, Oslo, Norway

**5:20-5:35 Discussant:** Pasi Janne, Boston, MA

**Bortezomib accelerates BAX BAK dependent mitochondrial depolarization in malignant pleural mesothelioma cells**  
Dean Fennell, Belfast, United Kingdom

**Cisplatin-induced apoptosis in malignant pleural mesothelioma cells involves p53 but not p14ARF**  
Thomas Marti, Zurich, Switzerland

**Anoikis resistance in malignant pleural mesothelioma cells**  
Julien Daubriac, Paris, France

**Role of Notch signaling in human malignant mesothelioma**  
Irene Graziani, Maywood, IL

**Bax and Bak immuno-reactivity in malignant pleural mesothelioma**  
Astero Klabatsa, London, United Kingdom

**Inhibition of survivin and aurora B kinase radiosensitizes mesothelioma cells by enhancing mitotic arrest**  
Bo Lu, Nashville, TN

**5:35-5:55 Discussant:** Giovanni Gaudino, Novara, Italy

## Posters

**DNA copy number profiling in malignant pleural mesothelioma by array CGH**  
Pamela Lindholm, Helsinki, Finland

**An integrated genomic approach to understanding the determinants of mesothelioma sensitivity to specific novel agents**  
Shigeki Shimizu, New York, NY

**SV40 infection can promote full oncogenicity of human mesothelial cells**  
Maurizio Bochetta, Maywood, IL

**Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients**  
Noriyasu Usami, Nagoya, Japan

**5:45-7:30 Reception at the Riverside Exhibition Hall Promenade  
Sheraton Chicago Hotel & Towers**

**Free evening to enjoy Chicago's wonderful restaurants and theaters**

**IMIG Board of Directors Meeting**

## **Saturday, October 21, 2006**

### **7:00-8:00 Continental Breakfast**

### **8:00-10:00 Non-Pleural Mesothelioma**

**Session Chairs:** Claire Vershraegen (Albuquerque, NM)  
and H. Richard Alexander (Baltimore, MD)

- 8:00-8:15 Mesotheliomas of the pericardium and tunica vaginalis**  
Raffit Hassan, Bethesda, MD
- 8:15-8:30 Understanding the terminology and pathology of peritoneal mesothelioma**  
Victor Roggli, Durham, NC
- 8:30-8:45 *Abstract:* Potential of survivin as a new therapeutic target in diffuse malignant mesothelioma of the peritoneum**  
Nadia Zaffaroni, Milan, Italy
- 8:45-9:05 Aggressive surgical cytoreduction with hyperthermic intraperitoneal chemoperfusion for patients with malignant mesothelioma**  
James Pingpank, Bethesda, MD
- 9:05-9:20 *Abstract:* Multimodality regional therapy for peritoneal mesothelioma**  
John Chabot, New York, NY
- 9:20-9:40 Diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Experience of NCI of Milan**  
Marcello Deraco, Milan, Italy
- 9:40-10:00 Prospective evaluation of quality of life after tumor cytoreduction and intraperitoneal chemotherapy in patients with peritoneal mesothelioma and other peritoneal surface malignancies**  
H. Richard Alexander, Baltimore, MD

### **Posters**

- Phase II trial of vinorelbine chemotherapy in patients with malignant peritoneal mesothelioma**  
Jeremy Steele, London, United Kingdom
- A systematic review on the efficacy of cytoreductive surgery combined with peri-operative chemotherapy for diffuse malignant peritoneal mesothelioma: An evolution of treatment strategies**  
Paul Sugarbaker, Washington, DC
- In vitro drug resistance levels do not correlate with prognosis in patients with peritoneal mesothelioma**  
Krunal Patel, New York, NY
- Critical analysis of nuclear size as an assessment of prognosis in diffuse malignant peritoneal mesothelioma**  
Paul Sugarbaker, Washington, DC

### **8:00-10:40 Workshop: Surgical Pitfalls and Challenges for Pleural Mesothelioma: Optimizing Your Technique**

David Sugarbaker (Boston, MA) and Walter Weder (Zurich, Switzerland)

- 8:00-8:20 Technical considerations of extrapleural pneumonectomy**  
David Sugarbaker, Boston, MA
- 8:20-8:35 Pericardial and diaphragmatic reconstruction**  
Hasan Batirel, Istanbul, Turkey
- 8:35-8:50 Techniques of intra-operative chemotherapy**  
Lambros Zellos, Boston, MA
- 8:50-9:10 Operative complications: Diagnosis and treatment**  
Walter Weder, Zurich, Switzerland
- 9:10-9:20 *Abstract:* Risk factors for major complications after extrapleural pneumonectomy**  
Marc de Perrot, Toronto, Canada
- 9:20-9:30 *Abstract:* Management of complications following extrapleural pneumonectomy**  
Hendrik Dienemann, Heidelberg, Germany
- 9:30-9:45 Pre-operative assessment and criteria for patient selection**  
Loic Lang-Lazdunski, London, United Kingdom
- 9:45-9:55 *Abstract:* Invasive staging for mesothelioma reveals radiographically occult distant metastatic disease**  
Joseph Friedberg, Philadelphia, PA
- 9:55-10:15 Pleurectomy/decortication for malignant pleural mesothelioma: Technique and comments**  
Harvey Pass, New York, NY
- 10:15-10:40 PANEL DISCUSSION**
- 10:20-11:45 Peritoneal Mesothelioma Workshop**  
**Co-Chairs:** Paul Sugarbaker (Washington, DC) and Raffit Hassan (Bethesda, MD)
- 10:20-10:35 Optimal treatment for patients with newly diagnosed peritoneal mesothelioma**  
James Pingpank, Bethesda, MD
- 10:35-10:50 Peritoneal mesothelioma: Treatment options for patients who are not candidates for surgery**  
Claire Vershraegen, Albuquerque, NM
- 10:50-11:05 Staging of peritoneal mesothelioma?**  
Paul Sugarbaker, Washington, DC
- 11:05-11:25 Multi-center clinical trials for peritoneal mesothelioma: Can they be done and what are the questions to be answered?**  
Raffit Hassan, Bethesda, MD



**11:25-11:45 PANEL DISCUSSION**

Claire Verschraegen (Albuquerque, NM), Victor Roggli (Durham, NC), James Pingpank (Bethesda, MD), Marcello Deraco (Milan, Italy) and H. Richard Alexander (Baltimore, MD)

**8:00-9:55 Epidemiology III: Oral Abstracts and Poster Discussion**

**Session Chairs:** James teWaterNaude (Capetown, South Africa) and Nicholas de Klerk (Subiaco, Australia)

**8:00-8:15 Abstract: Exposure to polio vaccine possibly contaminated with simian virus 40 and subsequent risk of malignant mesothelioma**  
Kristina Kjaerheim, Oslo, Norway

**8:15-8:30 Abstract: Malignant mesothelioma as a second primary malignancy**  
Sjaak Burgers, Amsterdam, The Netherlands

**8:30-8:45 Abstract: The mesothelioma epidemic and the hidden asbestos lung cancer epidemic**  
Christine Rake, Surrey, United Kingdom

**8:45-9:00 Abstract: Quantifying the risks of mesothelioma and lung cancer from environmental crocidolite exposure in Da-yao, China**  
Ting-Yuan David Cheng, Baltimore, MD  
**IMIG Young Investigator Award**

**9:00-9:15 Abstract: The French National Mesothelioma Surveillance Program**  
Marcel Goldberg, Saint-Maurice, France

**Poster discussion**

**Quantitative estimation of the risk of lung cancer and pleural mesothelioma among automobile mechanics in France**  
Marcel Goldberg, Saint-Maurice, France

**A cluster of 5 cases of malignant pleural mesothelioma among the faculty of a university asbestos insulated campus**  
Marcel Goldberg, Saint-Maurice, France

**Occupational asbestos exposure, possible mesothelioma, and reimbursement**  
Paul Baas, Amsterdam, The Netherlands

**Trend of mesothelioma morbidity in the Sverdlovsk Region of the Russian Federation**  
Sergey Kashansky, Ekaterinburg City, Russian Federation

**9:15-9:35 Discussant:** James teWaterNaude, Capetown, South Africa

**9:35-9:55 Discussant:** Nicholas de Klerk, Subiaco, Australia

**Posters**

**Benign neoplasms of the pleura in the structure of mesothelioma incidence**  
Sergey Kashansky, Ekaterinburg City, Russian Federation

**Risk assessment of malignant pleural mesothelioma related to long-term exposure to radiation factors**  
Sergey Kashansky, Ekaterinburg City, Russian Federation

**Mesothelioma in Russia: Review of 3,259 published cases**  
Sergey Kashansky, Ekaterinburg City, Russian Federation

**Prognostic factors and survival of malignant mesothelioma in Korea**  
Hyoung-Ryoul Kim, Seoul, Korea

**Clinico-pathologic analysis of malignant mesothelioma in Korea**  
Soon-Hee Jung, Wonju, Korea

**Asbestos problems in India: A revisit**  
V. Subramanian, New Delhi, India

**10:30-11:10 The High-Risk Individual III: Poster Discussion**

**Session Chair:** Robert Kratzke (Minneapolis, MN)

**DNA methylation profile of 28 candidate marker loci in malignant mesothelioma**  
Ite Laird-Offringa, Los Angeles, CA

**Asbestos exposure and genetic susceptibility to malignant pleural mesothelioma**  
Stalo Karageorgi, Boston, MA

**Effects of long-term supplementation with retinol on plasma, malignant mesothelioma, lung cancer, and potential side effects in the Wittenoom cohort**  
Helman Alfonso, Crawley, Australia

**10:30-10:50 Discussant:** Robert Kratzke, Minneapolis, MN

**Predictive and/or a diagnostic significance of serum soluble mesothelin related proteins in asbestos-related pleural malignant mesothelioma: Follow-up of a large population of workers previously exposed to asbestos**  
Luciano Mutti, Vercelli, Italy

**Discovery and validation of novel serological biomarkers of mesothelioma**  
Anil Vachani, Philadelphia, PA

**Prediagnostic soluble mesothelin related protein, CA125, CYFRA 21-1 and risk of mesothelioma: A case-control study**  
Oluf Dimitri Roe, Trondheim, Norway

**10:50-11:10 Discussant:** Harvey Pass, New York, NY

## Posters

### Analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma in a general population study

Marta Betti, Novara, Italy

### Low-dose computed tomography in workers previously exposed to asbestos: Detection of parenchymal lung disease

Demetris Patsios, Toronto, Canada

### Low-dose computed tomography in prior asbestos-exposed workers: Assessment of pleural plaques and screening for lung cancer and malignant mesothelioma

Hamid Bayanati, Toronto, Canada

### Soluble mesothelin-related protein is a useful biomarker for malignant mesothelioma developed in Japan

Kazuya Fukuoka, Hyogo, Japan

### Combination of cell-surface and soluble mesothelin expressions are required to discern epithelioid mesothelioma cells

Marc Gregoire, Nantes, France

### Serum tumor marker of human asbestos-related mesothelioma: Translational research from a hereditary rat cancer model

Okio Hino, Tokyo, Japan

### Re-evaluation of plasma osteopontin as a tumor marker for mesothelioma

Kazu Shiomi, Tokyo, Japan

### 8:00-11:45 Apoptosis Satellite Symposium

Co-Chairs: Courtney Broaddus (San Francisco, CA) and Dean Fennell (Belfast, United Kingdom)

#### 8:00-8:15 An apoptosis primer

Dean Fennell, Belfast, United Kingdom

### Session I: Intrinsic pathway and caspases

#### 8:15-8:35 BCL-2 family members in mesothelioma

Michael Lind, Hull, United Kingdom

#### 8:35-8:55 Small molecule inhibition of the BCL-2 family

Saul Rosenberg, Chicago, IL

#### 8:55-9:15 Regulation of cell survival in malignant pleural mesothelioma by Inhibitor of Apoptosis Proteins

Gavin Gordon, Boston, MA

#### 9:15-9:30 DISCUSSION

### Session II: The extrinsic pathway and its regulation

#### 9:30-10:00 A novel role of the death receptor CD95 as a tumor promoter

Marcus Peter, Chicago, IL

#### 10:00-10:20 TRAIL and damage pathways converge to induce synergistic apoptosis

Courtney Broaddus, San Francisco, CA

#### 10:20-10:30 DISCUSSION

### Session III: Resistance pathways

#### 10:30-10:50 Three-dimensional models of mesothelioma and multi-cellular apoptotic resistance

Dario Barbone, San Francisco, CA

#### 10:50-11:10 Wnt targeted therapies for mesothelioma

David Jablons, San Francisco, CA

#### 11:10-11:30 Receptor tyrosine kinase pathways and cell survival in mesothelioma

Giovanni Gaudino, Novara, Italy

#### 11:30-11:45 DISCUSSION

### 11:45-1:00 Joint Lunch with the attendees of the Mesothelioma Applied Research Foundation Symposium

### 1:00-3:10 Surgery and Multi-Modality Therapy for Pleural Mesothelioma: Controversy and Consensus

Session Chairs: Hasan Batirel (Istanbul, Turkey) and Wickii Vigneswaran (Chicago, IL)

#### 1:00-1:15 Pre-operative staging with CT/PET

Mylene Truong, Houston, TX

#### 1:15-1:25 Abstract: Role of preoperative staging procedures using conventional CT-scan, FDG-PET-CT-scan fused imaging, and mediastinoscopy compared to surgical-pathological findings in malignant pleural mesothelioma undergoing extrapleural pneumonectomy

Jens Benn Sorensen, Copenhagen, Denmark

#### 1:25-2:05 DEBATE

#### There is no role for radical surgery in the management of pleural mesothelioma

Tom Treasure, London, United Kingdom

#### Surgery for malignant pleural mesothelioma: A guaranteed complete response

Raja Flores, New York, NY

Moderator: Nicholas Vogelzang, Las Vegas, NV

#### 2:05-2:20 Safe implementation of intensity modulated radiation therapy (IMRT) for mesothelioma

Craig Stevens, Tampa, FL

#### 2:20-2:35 Integrating chemotherapy into multi-modality treatment

Rolf Stahel, Zurich, Switzerland

**2:35-2:45 Abstract: Multi-center phase II trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma**  
Lee Krug, New York, NY

**2:45-2:55 Abstract: Induction chemotherapy with cisplatin/gemcitabine compared to cisplatin/pemetrexed followed by extrapleural pneumonectomy for malignant pleural mesothelioma**  
Walter Weder, Zurich, Switzerland

**2:55-3:10 The scientific basis of integrated multimodality regimens**  
Bruce Robinson, Perth, Australia

#### Posters

**Lung sparing intrapleural and systemic chemotherapy plus intrapleural radiation for pleural mesothelioma: The Columbia protocol**  
Robert Taub, New York, NY

**Sequential amifostine and sodium thiosulfate improve renal protection during intracavitary high-dose cisplatin lavage**  
William Richards, Boston, MA

**Extrapleural pneumonectomy with adjuvant chemo-radiotherapy for treatment of malignant pleural mesothelioma**  
Rabab Gaafar, Cairo, Egypt

**Induction chemotherapy, extrapleural pneumonectomy, and adjuvant hemithoracic radiation in malignant pleural mesothelioma: A single center experience**  
Federico Rea, Padua, Italy

**Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma**  
Marc de Perrot, Toronto, Canada

**The Mesothelioma and Radical Surgery (MARS) trial update**  
Tom Treasure, London, United Kingdom

**Tri-modality treatment of malignant pleural mesothelioma in Turkey**  
Hasan Batirel, Istanbul, Turkey

**Successful multi-modal treatment in primarily chemo-resistant pleural mesothelioma**  
Helge Bischoff, Heidelberg, Germany

**Developing a program for post-operative IMRT in mesothelioma patients following pleurectomy plus phototherapy**  
Malcolm Feigen, Heidelberg, Australia

**Impact of integrated PET-CT on the selection of patients with malignant pleural mesothelioma for radical surgery (extra-pleural pneumonectomy)**  
Loic Lang-Lazdunski, London, United Kingdom

#### 3:10-3:40 Break/Poster Viewing

#### 3:40-5:55 Chemotherapy: Where Are We and Where Are We Going?

**Session Chairs:** Jeremy Steele (London, United Kingdom) and Christian Manegold (Mannheim, Germany)

**3:40-4:00 New insights into the mechanisms of action of pemetrexed in mesothelioma**  
I. David Goldman, Bronx, NY

**4:00-4:10 Abstract: Pemetrexed but not vinorelbine and cisplatin cytotoxicity is enhanced by COX-2 inhibitors in mesothelioma cell lines**  
Michael Lind, Hull, United Kingdom

**4:10-4:20 Abstract: Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed-induced cell death**  
Rongbao Zhao, Bronx, NY

**4:20-4:40 Combination chemotherapy: Moving beyond pemetrexed**  
Jan van Meerbeeck, Ghent, Belgium

**4:40-4:50 Abstract: Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma**  
Giovanni Luca Ceresoli, Milan, Italy

**4:50-5:00 Abstract: Pemetrexed second-line treatment in malignant pleural mesothelioma following platinum-based first-line treatment**  
Jens Benn Sorensen, Copenhagen, Denmark

**5:00-5:10 Abstract: Vinflunine in first-line treatment of malignant pleural mesothelioma: Final results of a European phase II study**  
Denis Talbot, Oxford, United Kingdom

#### The current status of clinical trials in:

**5:10-5:25 North America**  
Lee Krug, New York, NY

**5:25-5:40 Europe**  
Paul Baas, Amsterdam, The Netherlands

**5:40-5:55 Australasia**  
Nick Pavlakis, Sydney, Australia

#### Posters

**Pemetrexed and carboplatin in advanced pleural mesothelioma: Evaluation of the activity and toxicity in a series of 178 chemo-naive patients**  
Bruno Castagneto, Casale Monferrato, Italy

**An epigenetic mechanism for capecitabine resistance in mesothelioma**  
Kavitha Kosuri, Columbus, OH

**Sequential topoisomerase targeting triplet chemotherapy with irinotecan/cisplatin followed by doxorubicin in patients with malignant pleural mesothelioma: A pilot phase II study**

Takashi Nakano, Hyogo, Japan

**Treatment of malignant pleural mesothelioma with gemcitabine, carboplatin, and liposomized doxorubicin (Caelyx): The CCG study from the Nordic Mesothelioma Groups**

Gunnar Hillerdal, Stockholm, Sweden

**Treatment with gemcitabine and vinorelbine as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma**

Giovanni Luca Ceresoli, Milan, Italy

**Combination chemotherapy with methotrexate, irinotecan, and doxorubicin in malignant pleural mesothelioma**

Kozo Kuribayashi, Hyogo, Japan

**Pemetrexed in combination with carboplatin for the treatment of patients with malignant mesothelioma**

Maximilian Papi, Rimini, Italy

### **7:00-9:30 Gala Reception at the International Museum of Surgical Science**

**6:15** Trolleys depart from the Sheraton Chicago Hotel & Towers

**7:00-9:30** Reception

**9:30** Trolleys return to the Sheraton Chicago Hotel & Towers

## **Sunday, October 22, 2006**

### **7:00-8:00 Continental Breakfast**

### **8:00-9:45 Novel Targets/Novel Agents I: Agents Currently in Clinical Trials**

**Session Chairs:** Robert Kratzke (Minneapolis, MN) and Luciano Mutti (Vercelli, Italy)

**8:00-8:20 Proteasome inhibitors for the treatment of malignant mesothelioma**

Luciano Mutti, Vercelli, Italy

**8:20-8:35 *Abstract:* Preclinical studies of the proteasome inhibitor bortezomib (Velcade) in malignant pleural mesothelioma**

Gavin Gordon, Boston, MA

**8:35-8:50 Angiogenesis in mesothelioma**

Sarita Dubey, San Francisco, CA

**8:50-9:10 Results of phase I clinical trials of adenoviral interferon- gene therapy for malignant mesothelioma and malignant pleural effusions**

Daniel Serman, Philadelphia, PA

**9:10-9:20 *Abstract:* Calponin-targeting oncolytic Herpes simplex virus (HSV-1) as a novel therapeutic agent for sarcomatous mesothelioma**

Katsuhito Takahashi, Osaka, Japan

**9:20-9:35 Histone deacetylase inhibitors**

Sunil Sharma, Las Vegas, NV

**9:35-9:45 *Abstract:* An assessment of Onconase for the treatment of mesothelioma using the CALGB and EORTC paradigms**

Joachim von Pawel, Gauting, Germany

### **Posters**

**Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307**

Pasi Janne, Boston, MA

**TGF-Beta inhibition augments adenoviral-IFN $\beta$  (Ad.IFN ) gene therapy in a murine mesothelioma model**

Samuel Kim, Philadelphia, PA

**Asbestos in the past, nanomaterials in the future?**

Vanessa Sanchez, Providence, RI

**COX-2 specific inhibitors demonstrate a cytotoxic effect independent of COX-2 protein status in vitro**

Michael Lind, Hull, United Kingdom

**Targeting thioredoxin reductase—a possible new treatment for malignant mesothelioma**

Katalin Dobra, Huddinge, Sweden

**Preclinical evaluation of histone deacetylase inhibitors in malignant mesothelioma**

Sunil Sharma, Las Vegas, NV

**9:45-10:05 Break**

**10:05-11:55 Novel Targets/Novel Agents II: Targets for the Next Generation of Clinical Trials**

**Session Chairs:** Ravi Salgia (Chicago, IL) and Daniel Serman (Philadelphia, PA)

**10:05-10:25 IGF pathway activation in mesothelioma**

Robert Kratzke, Minneapolis, MN

**10:25-10:35 *Abstract:* Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis**

Cecelia Camacho-Hubner, London, United Kingdom

**10:35-10:55 c-met/HGF activation**

Ravi Salgia, Chicago, IL

**10:55-11:15 A novel small molecule inhibitor of TGF-beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection**

Steven Albelda, Philadelphia, PA

**11:15-11:25 *Abstract:* A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma**

Peter Szlosarek, London, United Kingdom

**11:25-11:40 *Abstract:* 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro**

Thomas Gauler, Essen, Germany

**11:40-11:55 Nanoporous spheres for drug delivery in mesothelioma**

Maria Ramos-Nino, Burlington, VT

**Posters**

**Molecular targeting of malignant pleural mesothelioma by c-met and ROS modulation**

Ramasamy Jagadeeswaran, Chicago, IL

**Tyrosine kinase inhibitor ZD6474 (Zactima) and its effects on malignant mesothelioma cell lines**

Betta Pier-Giacomo, Alessandria, Italy

**Activation of 4E-BP1 represses IGF-1 mediated cap dependent translation in malignant pleural mesothelioma**

Blake Jacobson, Minneapolis, MN

**RNA interference against Hec1 targets malignant mesothelioma**

Zeng Zhu, Birmingham, AL

**MET in mesothelioma: Mutational screening, phosphorylation status, and sensitivity to the MET inhibitor PHA-665752**

Shigeki Shimizu, New York, NY

**Biocompatible, hydrophilic, supramolecular carbon nanoparticles for cell delivery**

Bonnie Lau, Providence, RI

**8:00-12:00 Pathology Workshop**

**Co-Chairs:** Thomas Colby (Rochester, MN), Francoise Galateau-Salle (Caen, France) and Aliya Husain (Chicago, IL)

**8:00-10:00 Session I: Current Status of Pathologic Diagnosis of Malignant Mesothelioma**

**8:00-8:20 Morphologic diagnostic criteria of mesothelioma**

Philip Cagle, Houston, TX

**8:20-8:40 Atypical mesothelial cell proliferations: Separating mesothelioma from reactive mesothelial hyperplasia**

Thomas Colby, Rochester, MN

**8:40-9:00 IHC evaluation**

Allen Gown, Seattle, WA

**9:00-9:20 Molecular studies in diffuse malignant mesothelioma of the pleura**

Francoise Galateau-Salle, Caen, France

**9:20-9:30 *Abstract:* MUC1 in malignant mesothelioma**

Jenette Creaney, Perth, Australia

**9:30-9:40 *Abstract:* Diagnostic value of proliferative markers Ki-67 and Repp 86 in distinction between malignant and benign mesothelial proliferations**

Zohreh Mohammadtaheri, Teheran, Iran

**IMIG Travel Award**

**9:40-9:50 *Abstract:* Prolonged survival in malignant mesothelioma: A study of 19 cases**

Francoise Galateau-Salle, Caen, France

**9:50-10:00 *Abstract:* Accuracy of pathological diagnosis of mesothelioma in Japan**

Kouki Inai, Hiroshima, Japan

**10:00-10:15 BREAK**

**10:15-12:00 Session II: The Use of Immunohistochemistry Panels in the Diagnosis of Mesothelioma: Guidelines and Recommendations**

**PANEL DISCUSSION**

**Posters**

**Differentiating between malignant mesothelioma and squamous cell carcinoma: An immunohistochemical study**

Tiffany Chang, Chicago, IL

**Diagnostic utility of GLUT-1 expression in the differential diagnosis between reactive mesothelium and malignant mesothelioma**

Yasufumi Kato, Tokyo, Japan

**Immunocytochemistry with ten commercially available antibodies in adenocarcinoma cells, malignant or reactive mesothelial cells in serous effusions**

Toshiaki Kamei, Hofu, Japan

**Prognostic value of fascin immunoreactivity in peritoneal mesothelioma**

Alain Borczuk, New York, NY

**Utility of CD138, estrogen receptor and progesterone receptor in the differential diagnosis of peritoneal mesothelioma and ovarian adenocarcinoma**

Alain Borczuk, New York, NY

**A case of malignant mesothelioma with rhabdomyosarcomatous differentiation**

Astero Klabatsa, London, United Kingdom

**Malignant mesothelioma with signet ring cell formation: A very rare presentation**

Sumru Beder, Ankara, Turkey

**Malignant tumor with bone formation in a man from Karain village: Mesothelioma or sarcoma?**

Gunnar Hillerdal, Stockholm, Sweden

**Pathological study of malignant pleural mesothelioma resected with extrapleural pneumonectomy**

Kenzo Hiroshima, Chiba, Japan

**12:00-12:05 Concluding Remarks**

Hedy Lee Kindler and Samuel Armato  
 IMIG Conference Co-Chairs

**12:05 Boxed Lunches**

## IMIG 2006

### Agenda at a Glance

Time	Main Session	Workshop 1	Workshop 2	Workshop 3
<b>Thursday</b>				
8:00	High-Risk Individual I			
10:00	High-Risk Individual II			
11:00	Pathogenesis			
2:30		Chemotherapy Workshop		Animal Models Workshop
<b>Friday</b>				
8:00	Epidemiology I			
10:00	Epidemiology II		Immunology Workshop	
2:00	Genetics			
4:00		Supportive Care Satellite	Tumor Biology: Oral abstracts and poster discussion	Imaging Workshop
<b>Saturday</b>				
8:00	Non-Pleural Mesothelioma		Epidemiology III: Oral abstracts and poster discussion	
10:00	Peritoneal Workshop	Surgical Techniques Workshop	High-Risk Individual: Poster discussion	Apoptosis Satellite
2:00	Surgery and Multimodality Therapy			
4:00	Chemotherapy			
<b>Sunday</b>				
8:00	Novel Agents/ Novel Targets I		Pathology	
10:00	Novel Agents/ Novel Targets II			

## CME Information

### Statement of Need

This international conference will be a highly interactive, trans-disciplinary meeting, the goals of which are to present scientific information of the highest caliber across disciplines, to foster international collaboration, to inspire new investigators, to generate new ideas, and to establish benchmark standards in this disease. The format will consist of invited lectures, oral abstract presentations, poster presentations, and poster discussion sessions. To foster collaboration and interaction, an important feature of this meeting will be interactive workshops and debates on key issues.

### Learning Objectives

After this conference, participants will:

- Understand the best screening methods for mesothelioma—biomarkers, CT scans, thoracoscopy—in patients exposed to asbestos;
- Understand the interaction between genetics and mineral exposure in the development of mesothelioma;
- Understand the mechanisms of the pathogenesis of mesothelioma;
- Describe the epidemiology of asbestos exposure and mesothelioma in countries around the world;
- Understand the genetic alterations caused by asbestos;
- Understand and optimize the clinical management of patients with peritoneal mesothelioma;
- Understand the different multimodality approaches for the management of pleural mesothelioma;
- Understand the activity of various chemotherapeutic agents in patients with mesothelioma;
- Understand the optimal therapeutic targets for the next generation of clinical trials for mesothelioma;
- Understand the clinical relevance of mouse models for mesothelioma;
- Understand key questions that need to be answered in order to develop the next generation of chemotherapy clinical trials for mesothelioma;
- Understand the immunology of mesothelioma and immunotherapeutic approaches for treatment;
- Understand the current controversies involved in imaging mesothelioma;
- Understand the key issues in supportive care for mesothelioma patients;
- Understand apoptosis in mesothelioma;
- Understand the optimal treatment, staging, and clinical trial design for peritoneal mesothelioma;
- Learn technical skills about the surgical management of mesothelioma;
- Understand the current status of the pathologic diagnosis of mesothelioma and make recommendations on the use of immunohistochemistry panels.

### Target Audience

Medical oncologists, surgeons, radiation oncologists, pulmonologists, epidemiologists, radiologists and basic scientists who research mesothelioma or treat patients with this disease.

### Accreditation

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

### Credit Designation

The University of Chicago Pritzker School of Medicine designates this educational activity for a maximum of 24.50 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### Additional Information

The University of Chicago  
The Center for Continuing Medical Education  
950 E. 61st Street, Room 101  
Chicago, IL 60637  
Phone: 773-702-1056  
Fax: 773-702-1736  
[cme@bsd.uchicago.edu](mailto:cme@bsd.uchicago.edu)  
<http://cme.uchicago.edu>

## Acknowledgements

## Notes

The conference organizers wish to extend our sincerest thanks to the following for financial support received for the IMIG meeting:

Cooney & Conway

Richardson, Patrick, Westbrook & Brickman, LLC

Kazan, McClain, Abrams, Fernandez, Lyons,  
Farrise & Greenwood

Law Office of Nicholas J. Vogelzang

Merck

Simmons Cooper, LLC

Terrence M. Johnson, Esq.

Eli Lilly and Company

AstraZeneca

Roger Worthington, PC

Cambridge Antibody Technologies

Bristol-Myers Squibb Oncology





**iMig**  
International Mesothelioma Interest Group

Devoted to the biology & pathology of mesothelial cells.